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The Neuroleptic Malignant Syndrome (NMS) is a potent ially grave adverse
reaction to oral or parenteral neuroleptic therapy that may be an underdiagnosed and
easily overlooked clinical problem. NMS is characterized by hypertherm ia, hyperten-
sion, diaphoresis, muscular rigidity, and altered mentation. There is currently no way
of predicting which patients will develop NMS, although its incidence may be higher in
patients who are unresponsive to usually effective dosages of neurol epti cs ( I) .
NMS was first described in the French literature by Delay and Deniker in 1960
(2) . They reported five cases among several hundred patients who were treated with
haloperidol (Haldol"), suggesting an incidence of approximately 0.5-1 .0%.
NMS typically occurs following the use of high potency neuroleptics in thera-
peutic dosages . The characteristic features of NMS have also been reported to occur
following the use of neuroleptics in combination with lith ium carbonat e, during
sedative-hypnotic withdrawal states, and following the use of MAO inhibitor-tr icyclic
antidepressant (2, 3) . Of the four cases we reported, two were attributable to
fluphenazine (Prolixinv). one to haloperidol, and one to thiothixene (Navanee).
The relationship between NMS and clinically similar hyperthermic reactions is
unclear at this time. NMS may represent the neuroleptic-induced subtype of a more
generalized syndrome that can be caused by a variety of pharmacologic agen ts in
susceptible individuals. If so, the question arises as to why certain pati ent s who receive
therapeutic dosages of neuroleptics are more susceptible to NMS than others.
Itoh and associates have noted that prior to the onset of NMS some patients have
suffered from physical exhaustion and dehydration (4). Other possible etiologic factor s
include age, sex, and race . Among cases reported in the literature, nearly eight y
percent were young males (although NMS has been reported in males and females of
all ages) . Race has not been reported to be a significant factor, but the four patients we
reported who developed NMS were all of African descent. Thi s group included three
males and one female with a mean age of 36.8 years.
The etiology of NMS may be related to neuroleptic-induced altera tion of central
neuroregulatory mechanisms (2). Neuroleptics are known to block dopamine receptors
in the basal ganglia and hypothalamus. Another hypothesis is that NMS may be a
muscular disorder. This theory is based on the inhibitory effect that phenothiazines can
exert on the uptake of calcium by the sarcoplasmic reticulum of skeleta l muscle (5);
this may lead to an excessive release of these ions into the cell's cytoplasm that can
cause prolonged muscle contraction. This effect is seen, however, only in suprathera-
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peutic dosages of phenothiazines, and has not been demon strated in other classes of
neuroleptics.
Once NMS begins , its signs and symptoms may develop explosively over the
course of one to three days. NMS may begin from a few hours to several months after
neuroleptic theory has been initiated. The cardinal feature of NMS is fever, a sign that
distinguishes NMS from other adverse reactions to neuroleptics (6) . Hyperthermi a
may be the result of blockage of dopamine receptors in the hypothalamus that control
thermoregulation. Intense muscle activity may also contribute to an increa se in body
temperature.
Muscle rigidity in NMS has been characterized as a generalized "lead pipe" or
" plastic" rigidity (2). Consciousness in NMS patients may fluctuate from an aler t but
dazed mutism to stupor and coma . Other features of this disorder include sialorrhea,
dyskinesias, dysphasia , and autonomic nervous system involvement (ma nifested by
severe tachycardia, labile blood pressure, profuse diaphoresis, dyspnea, and incont i-
nence) . Bizarre posturing and waxy flexibility have also been reported (6) .
Recovery following appropriate treatment may be slow, and irr eversible brain
damage has been reported (sustained in a patient who suffered card iac arrest during
anesthesia while receiving electroconvulsive therapy (ECT) for NMS (7» . Fat alities
typically occur three to thirty day s after onset of NMS, usually resulting from
respiratory or renal failure, cardiovascular collapse, or arrhythmi as. N MS is estimated
to have a mortality rate of about twenty percent (2) . Mortali ty may be greater when
hyperthermia is more severe and prolonged. One patient we repor ted with NMS had
severe prolonged hyperthermia (around 104°) despite supportive measures and other
treatment; this patient eventually developed a consumptive coagulopathy and died.
Laboratory examination may reveal severa l abnormaliti es comm on to NMS, and
is essential in order to rule out other disorders. In NMS there may be leukocytosis
ranging from 15,000 to 30,OOO/cu mm. Serum creatinine phosphok inase (C PK) is
almost always markedly elevated, having been reported in one patient to be 15,400 I.U.
(2,8) .
Prior to establishing the diagnosis of NMS and initiating appropriate treatment,
man y other disorders must be excluded. The differential diagnosis of NMS must
include the following.
1) Other known causes of CPK elevation, including damage or inju ry to muscle
such as may occur in strokes, convulsions, myocardial infarct ion, trauma,
multiple intramuscular injections, and muscular dystrophy. Spec ific isoenzyme
assays may help to differentiate these conditions (9) .
2) Idiopathic malignant hyperthermia (MH) , an autosomal domin ant disorder seen
during or after general anesthesia, especially following the use of inhalational
anesthetics or depolarizing muscle relaxants. Indeed some reports sugges t that
cases of NMS resulting from preoperative use of neurol eptics may have been
misdiagnosed as MH (2, 10). NMS and MH differ in ways besides having
separate triggering agents. Curare does not a lleviate rigid ity associated with
MH, but in one patient with NMS it led to flacidit y and dimini shed hyperpyrex-
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ia. Mortality from MH approaches seventy percent, but is less than twenty-five
percent in NMS. Mild muscle enzyme elevations persist in most patients with
MH, but are normal before and after NMS (10).
3) Acute lethal catatonia, perhaps the most difficult condition to distinguish from
NMS on a clinical basis (6) . In the early literature, acute lethal catatonia was
described as beginning with psychosis and intense motor excitement, followed by
clouding of consciousness, cyanosi s, marked temperatu re elevations, and a drop
in blood pressure. Treatment of this disorder includes aggressive supportive care,
adrenal cortical extract, neuroleptics, and ECT.
4) Drug-induced hyperthermia and heat stroke , an exampl e of which is anticholin-
ergic intoxication, which may result from various medications and is known to
cause impairment of sweating mechanisms, result ing in hyperpyrexia. Unlike
NMS, however, muscular rigidity is an uncommon finding in heat stroke.
5) Infections of the central nervous system, especially viral encephalitis, must be
ruled out (2, II). Acute viral enceph alitis may presen t as an acute febrile sta te
with evidence of meningeal involvement, as well as the following signs and
symptoms: convulsions, confusion, stupor, coma, aphasia, mutism, hemiparesis,
positive Babinski signs, involuntar y movements , ataxia, myoclonic jerks, nystag-
mus, ocular palsies, and facial weakness. The diagnosis of viral enceph aliti s
depends on examination of the cerebrospinal fluid (CS F), which typically reveals
mononuclear and lymphocytic pleocytosis, a small increase in CSF protein,
normal CSF glucose , and negative smears and cultures (12).
6) Collagen-vascular and neoplastic lesions of the central nervous system, the
criteria for the diagnosis of which should be based on the tempo of the clinical
syndrome, evidence of focal brain disease, the clinical setting, and appropriate
laboratory investig ations.
7) Severe extrapyramidal reactions, which includ e Parkinsonism, muscle spasms,
dystonias, dyskinesias, akathesia , and tardive dyskinesia ( II).
8) Other causes ofrigidit y, including decerebrate rigidity, hyster ical rigidity, St iff
Man Syndrome, tetanus rigidity, and strychnine rigidity (2).
9) Other possible disorders, include akinetic mutism, encepha litis lethargica, and
locked-in syndrome (2.)
Measurement of serum CPK would seem to be the best monitor of NMS. Serum
CPK is not usually elevated in cases of fever alone and is usually higher in NMS than it
is in cases of extrapyramidal reactions, catatonic states, idiopathic malignant hyper -
thermia, or the acute organic brain syndromes mentioned above (1 1).
Treatment of NMS is predicated on early recognition of its signs and symptoms.
Every patient who is being treated with intramuscular neuroleptic medicat ion should
be monitored hourly for changes in vital signs and earl y evidence of extrapyramidal
reactions or central nervous system toxicity. Whenever a pat ient does not respond to
usually effective dosages of an intramuscular neuroleptic, he or she should be
considered refractory to treatment and another modality substituted (1, 13).
Once the diagnosis of NMS is made, the neuroleptic being used must be
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discontinued immediately and supportive measures instituted. Supportive care should
include treatment in an intensive care setting with monitoring of respiratory, cardio-
vascular, and renal systems. Fluid and electrolyte balance must be closely watched. Ice
packs or alcohol sponges may be useful in lowering the body temperat ure (I, 13).
Promising results have been reported following the use of bromocriptine
(Parlodelv) , now considered a novel treatment for NMS (Ll , 13). Dramatic improve-
ment has been reported after its use in small dosages from 15 to 30 mg. per day. As a
dopamine agonist bromocriptine may act to reverse the effects of neuroleptic medica-
tion in the central nervous system, it has been proven to lower body temperature and
lessen muscle rigidity and akathisia. One might expect that because it is a dopamine
agonist that bromocriptine might exacerbate psychosis. Moreover, while bromocrip-
tine is a recognized agent for the treatment of Parkinson's disease, its use in
drug-induced Parkinsonism has not yet been approved (l4) .
Amantadine (Symmetrele) is another dopamine agoni st that has been reported to
be successful in treating the symptoms of NMS (l3) . Dosages averaging 200 mg. daily
have been reported to effect rapid improvement in NMS within severa l days. Again,
because amatadine is a dopamine agonist, some worsening of psychosis might be
expected.
Some authors have claimed success using dantrolene sodium (Dantri ume) , a
direct-acting muscle relaxant that has also been shown to be effective in M H (l O, 13).
Dantrolene acts by inhibiting the release of calcium ions from skelet al muscle, thereby
ameliorating rigidity and helping to reduce body temperature. It remains unclear,
however, whether favorable results may be attributable to dantrolene alone, since in
most cases its use has been associated with concomitant discont inuat ion of neurolep-
tics . Recommended dosages for dantrolene have been from 200 to 300 mg. daily.
Still other authors have claimed remarkable success , especially in rapidl y
deteriorating patients when other modalities have failed, using electroconvulsive
therapy (6). Improvement in the symptoms of NMS, including a marked redu ct ion in
body temperature, is felt to result from an increase in dopamine turnover in the brain.
ECT may be particularly useful in the treatment of catatonia accompan ied by fever.
CASE REPORT
Mr. S. was a thirty-three-year-old black male who was received from the city jail
in handcuffs. Upon initial evaluation he was noted to be extremely agit ated, irrita ble,
restless, confused, and paranoid. He had a long history of manic episodes that were
apparently precipitated by stress and alcohol abuse.
Mr. S. was initially treated with thiothixene, 10 mg. every four hours times four
dosages, then 10 mg. every six hours times eight dosages . All dosages were admi nis-
tered intramuscularly. Twenty-four hours after his initial injection, Mr . S. began to
sweat profusely, refused to eat, became lethargic and demonstrated marked akat hisia
and rigidity. His temperature, initially 98.4° , rose to 101.2°. His blood pressure was
170/95 mg Hg. His pulse was 122 per minute. Subsequently the patient became
drowsy and was transferred to the intensive care unit, where supportive measures were
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instituted. Mr. S . was begun on bromocriptine, 5 mg. three times daily, and diazepam
(Valium w), 10 mg. three times daily.
Four hours after Mr. S. received his first dose of bromocrip tine, improvements
were noted in his rigidity, akathisisa, and sensorium. His blood pressure and tempera-
ture returned to normal within twenty-four hours. His serum CPK level, initia lly 1553
IV , and white blood cell count, initially 16,400/cu mm, also returned to within normal
limits within five days after treatment had begun. Mr. S. was gradu ally weaned from
medication and subsequently discharged two weeks later.
DISCUSSION
An increasing number of physicians are learning about NMS, a potentially lethal
condition that may be underdiagnosed. As time goes on a grea ter number of
neuroleptics are being implicated in the etiology of N MS. The picture is clouded,
however, by the number of patients who develop NMS who are concomitantly
receiving other medications (including other neuroleptics). Hopefully, the increase in
physicians' awareness of this disorder and promising new modes of treatment will
combine to minimize the morbidity and mortality that may resul t from N MS.
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